G protein-coupled receptors (GPCRs) represent the largest family of drug targets and are central to Parkinson's disease therapeutics. The basal ganglia's dopaminergic signaling network, modulated by adenosine and other GPCR systems, offers multiple validated targets for disease modification and symptom control. This page catalogs companies developing GPCR-targeting therapies for PD across different mechanism categories.
The PD GPCR therapeutics market encompasses several key segments:
Headquarters: Japan
Pipeline Status: Marketed (Japan), Phase 3 (US/EU)
Kyowa Kirin developed and markets istradefylline (Nourianz), an adenosine A2A receptor antagonist approved in Japan (2013) for Parkinson's disease as an adjunct to levodopa-carbidopa therapy. The company has pursued global development, with tozadenant (SYN115) acquired from Biotie Therapies advancing through clinical trials[1].
Key Programs:
Mechanism: A2A receptor antagonism modulates striatopallidal pathways, reducing excessive inhibition of thalamocortical motor output without causing dyskinesias. The A2A-dopamine D2 receptor interaction in the striatum provides a validated therapeutic target[2].
Clinical Evidence: Multiple Phase 2/3 trials demonstrate statistically significant improvements in OFF-time reduction and ON-time increase without worsening dyskinesias[3].
Headquarters: Finland (acquired)
Status: Integrated into Kyowa Kirin
Biotie was a pioneer in A2A antagonist development, with tozadenant (SYN115) advancing to Phase 3 trials. The company's virtual model enabled rapid clinical development before acquisition by Kyowa Kirin in 2016.
Key Programs:
Headquarters: United States
Pipeline Status: Research/Preclinical
Eli Lilly has a long history in dopamine agonist development and continues to invest in next-generation dopamine receptor therapeutics for Parkinson's disease.
Key Programs:
Headquarters: Japan
Pipeline Status: Phase 2
Astellas is developing ASP7542, a novel selective dopamine D1/D5 receptor agonist for Parkinson's disease[4].
Key Programs:
Mechanism: Direct activation of D1/D5 receptors in the striatum and cortex provides dopaminergic stimulation without the need for dopamine metabolism. D1 agonists may offer advantages in addressing both motor and non-motor (cognitive, mood) symptoms.
Headquarters: United States
Pipeline Status: Preclinical
Neurocrine Biosciences focuses on disorders of the brain and endocrine system, with programs targeting dopaminergic signaling pathways.
Key Programs:
Headquarters: Japan
Pipeline Status: Marketed (Japan)
Pharma Two B markets pramipexole and develops next-generation dopamine agonists with improved pharmacological profiles.
Key Programs:
Headquarters: United States
Pipeline Status: Approved (schizophrenia), Investigational (PD)
Karuna's lead program KarXT (xanomeline-trospium) combines a selective muscarinic M1/M4 agonist (xanomeline) with a peripheral antagonist (trospium) to achieve CNS activity while minimizing peripheral side effects. While initially developed for schizophrenia, muscarinic modulation has relevance for PD cognition and psychosis[5].
Relevance to PD:
Clinical Status: Approved for schizophrenia (2024); PD studies anticipated.
Headquarters: United States
Pipeline Status: Marketed (PD psychosis)
Acadia's pimavanserin (Nuplazid) is a selective serotonin 5-HT2A inverse agonist approved for Parkinson's disease psychosis. While not a traditional GPCR agonist, it modulates serotonin signaling through a unique mechanism[6].
Key Programs:
Headquarters: United States
Pipeline Status: Marketed
As above, Acadia's pimavanserin targets 5-HT2A receptors to treat PD psychosis without worsening motor symptoms—an advantage over dopamine antagonists[7].
Mechanism: Inverse agonism at 5-HT2A receptors reduces psychotic symptoms without D2 receptor blockade, avoiding motor worsening.
Headquarters: United States
Pipeline Status: Investigational
BMS acquired Karuna and continues development of muscarinic programs with potential applications in PD neuropsychiatric symptoms.
GPR6 is an orphan GPCR highly expressed in the striatum. Modulation of GPR6 may offer a novel approach to Parkinson's disease through effects on dopaminergic signaling and neuroprotection. Companies including Biogen and Amgen have disclosed early-stage programs targeting GPR6.
Relevant page: GPR6 Modulator Therapy
The oxytocin system has been implicated in social cognition and may offer benefits for PD depression and anxiety. Early-stage programs explore oxytocin receptor modulation.
Relevant page: Oxytocin Receptor Modulators
Neurotensin signaling interacts with dopaminergic pathways and may provide disease-modifying effects in PD.
Relevant page: Neurotensin Receptor Modulators
| Company | Drug/Program | Target | Phase | Indication |
|---|---|---|---|---|
| Kyowa Kirin | Istradefylline (Nourianz) | A2A Antagonist | Marketed (JP) | PD adjunct therapy |
| Kyowa Kirin | Tozadenant (SYN115) | A2A Antagonist | Phase 3 | Motor fluctuations |
| Astellas | ASP7542 | D1/D5 Agonist | Phase 2 | PD motor symptoms |
| Pharma Two B | Pramipexole | D2/D3 Agonist | Marketed | PD therapy |
| Acadia | Pimavanserin | 5-HT2A Inv. Agonist | Marketed | PD psychosis |
| Karuna/BMS | KarXT | M1/M4 Agonist | Investigational | PD cognition |
The dopaminergic system comprises five receptor subtypes (D1-D5) grouped into D1-like (D1, D5) and D2-like (D2, D3, D4) families. Parkinson's disease involves progressive loss of substantia nigra dopaminergic neurons, leading to deficient striatal dopamine signaling. GPCR-based therapies restore or modulate this signaling:
Adenosine A2A receptors are highly expressed in the striatum, forming heteromers with dopamine D2 receptors. A2A activation reduces D2 receptor affinity for dopamine, contributing to motor inhibition. A2A antagonism removes this inhibition, improving motor function without direct dopaminergic stimulation—potentially providing disease-modifying effects.
Cholinergic signaling through muscarinic receptors (M1-M5) modulates both motor and cognitive functions. M1/M4 agonists may improve cognition while M3 antagonism could reduce dyskinesias.
Adenosine A2A receptors and Parkinson's disease. Nat Rev Neurol. 2019. ↩︎
Adenosine A2A receptors and Parkinson's disease: therapeutic prospects. Br J Pharmacol. 2011. ↩︎
Istradefylline: a review in Parkinson's disease. CNS Drugs. 2019. ↩︎
Dopamine D1/D5 receptor agonists in Parkinson's disease. Brain. 2022. ↩︎
KarXT (xanomeline-trospium) in schizophrenia and beyond. Nat Rev Drug Discov. 2024. ↩︎
5-HT2A inverse agonists for Parkinson's disease psychosis. J Pharmacol Exp Ther. 2023. ↩︎
Serotonin receptor modulators in Parkinson's disease psychosis. Mov Disord. 2022. ↩︎